• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Hyperthermic intraperitoneal chemotherapy may be less risky than expected

bys25qthea
December 21, 2013
in Chronic Disease, Oncology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery had a 2% 30-day mortality. 

2. Large prospective trials are necessary to confirm the role of HIPEC in the modern therapeutic regimen. 

Evidence Rating Level: 2 (Good)

Study Rundown: The management of peritoneal carcinomatosis is split between systemic and HIPEC. HIPEC allows the administration of locally high concentrations of therapeutic agent in combination with temperatures cytotoxic to malignant cells. It has been demonstrated that surgery combined with HIPEC can improve long-term survival in carefully selected colorectal, appendiceal, and primary peritoneal cancer patients with good performance status and low volume of peritoneal disease. However, it is a complicated procedure with a lack of evidence demonstrating its superiority over systemic chemo making it an uncommon choice of treatment. This study set out to report morbidity and mortality data on a large set of HIPEC patients, and found an overall 30-day morbidity and mortality of 33% and 2%, respectively. However, this study’s results may have been swayed by greater expertise in participating hospitals than available nationwide. While the low 30-day mortality is a convincing indicator that treatment-associated deaths are within acceptable limits, prospective trials with longer-term follow-up are necessary to confirm the safety and efficacy of HIPEC.

Click to read the study in JAMA Surgery

Relevant Reading: Intraperitoneal chemotherapy: Rationale, applications, and limitations

RELATED REPORTS

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

In-Depth [retrospective cohort]: A total of 694 HIPEC cases with cytoreductive procedures occurring 2005-2011 were culled from the American College of Surgeons National Surgical Quality Improvement Program database. Primary endpoints were overall 30-day mortality and morbidity. Patient and treatment characteristics were used to build predictive models for respiratory complications, septic shock, and return to the OR based on the Lasso algorithm. Appendiceal cancer was present in 14% of patients, primary peritoneal in 11%, and colorectal cancer in 8%. Overall mortality was 2.3%, mostly after post-op day 17, and 9.8% of patients returned to the OR. Postoperative bleeding requiring transfusion occurred in 17% of patients, septic shock in 16%, pulmonary complications in 15%, and organ-space infections in 9% of patients. Analysis failed to identify any strong predictors of morbidity or mortality.

By Mariya Samoylova and Allen Ho

More from this author: Resident involvement linked with more complications in joint surgery; Promising liver transplant outcomes at 20 years; Transfusion worsens outcomes for HCV+ liver transplant recipients; Endovascular repair of ruptured AAAs no better than open repair ; Longer preoperative treatment of pancreatic cancer may extend survival

©2012-2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: chemotherapy
Previous Post

Surgeons may be unaware of own level of burnout

Next Post

Prenatal inflammatory markers associated with adverse neonatal outcomes

RelatedReports

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
StudyGraphics

#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer

April 28, 2022
Next Post
Buccal administration of dextrose gel effective for neonatal hypoglycemia

Prenatal inflammatory markers associated with adverse neonatal outcomes

Antepartum and intrapartum events both linked to neonatal HIE

New risk stratification algorithm suggested for neonatal sepsis

Bariatric surgery is an effective option for weight loss and glycemic control

Earlier adiposity rebound associated with worse metabolic markers

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Criteria for low-dose computed tomography lung cancer screening omit a high risk population of smokers
  • CT scans increase the risk of malignancy in children and young adults [Classics Series]
  • Weighted blankets may reduce sleep medication use in psychiatric patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.